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Abstract: The search for antiepileptic compounds with more selective activity and lower toxicity continues to be an area
of intensive investigation in medicinal chemistry. This review describes new anticonvulsant agents representing various
structures for which the precise mechanism of action is still not known. Many of the compounds presented in this review
have been tested according to the procedure established by the Antiepileptic Drug Development Program of the Epilepsy
Branch of the National Institute of Neurological Disorders and Stroke, National Institute of Health, USA. The newer
agents include sulfonamides, amino acids, amides (analogs of γ-vinyl GABA, N-benzylamides, 2,6-dimethylanilides,
carboxyamides, hydroxyamides, alkanoamides); heterocyclic agents ((arylalkyl)imidazoles, pyrrolidin-2,5-diones,
lactams, semi- thiosemicarbazones, thiadiazoles, quinazolin-4(3H)-ones, 2,5-disubstituted 1,2,4-thadiazoles, xanthones,
derivatives of isatin) and enaminones. These new structural classes of compounds can prove useful for the design of future
targets and development of new drugs.
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INTRODUCTION
Epilepsy is a common neurological condition, affecting
0.5 to 1% of the population worldwide (45-100 million
people) [1]. Conventional antiepileptic drugs (AEDs) pheno-
barbital, primidone, phenytoin, carbamazepine, ethosuximide
and benzodiazepine, are widely used but exhibit an
unfavorable site effect profile and failure to adequately
control seizures. In the recent years several new drugs
(oxcarbazepine, lamotrigine, topiramate, gabapentin,
zonisamide, tiagabine, fosphenytoin, vigabatrin and
felbamate) have been added to the list of therapeutic agents
against epilepsy. However, there is a significant group of
patients (up to 30%) who are resistant to the available
antiepileptic drugs. The long-established AEDs control
seizures in 50% of patients developing partial seizures and in
60-70% of those developing generalized seizures [2-6].
Hence, there is an urgent need to develop new AEDs [7].
The search for antiepileptic compounds with a more
selective activity and lower toxicity continues to be an area
of investigation in medicinal chemistry. A rational drug
design process of a new anticonvulsant could be achieved in
several ways [8, 9]. The first strategy is the identification of
new targets through better understanding of molecular
mechanisms of epilepsy. Another way is to modify already
existing drugs and formulations. AEDs belong to many
different chemical classes of compounds, including:
hydantoines, iminostilbenes, barbiturates, benzodiazepines,
valproate, imides, oxazolidine-2,3-diones, sulfonamides and
miscellaneous agents [10]. The efficacy of AEDs is due to
the main activities which include interaction with ion
channels or neurotransmitter systems [11-17]. Currently
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available AEDs can be broadly classified into four
categories: (1) those whose main action relates to the
inhibition of sustained repetitive firing, through blockage of
voltage-dependent sodium channels and consequent
inhibition of the release of excitatory neurotransmitters
(phenytoin, carbamazepine, oxcarbazepine); (2) those which
enhance GABA-ergic transmission (benzodiazepines, barbit-
urates, vigabatrin, tiagabine); (3) those stabilizing thalamic
neurons through inhibition of T-type calcium channels
(ethosuximide) and (4) those possessing a combination of the
above actions, often coupled with additional mechanisms
(valproic acid, gabapentin, lamotrigine, topiramate,
zonisamide, felbamate). However, this classification has
limited value because the majority of AEDs possess more
than one mechanism of action, which may account for their
efficacy, and it is also the fact that some of the clinically
used drugs have not been linked with a specific site the
brain, and the exact mechanisms of many AEDs remain
unknown [18,19].
The new AEDs and anticonvulsant agents have been
reviewed during last few years [20-24]. The chemical
diversity and various mechanisms of action of anticon-
vulsants make it difficult to find a common way of
identifying new drugs. Novel anticonvulsant agents are
discovered through conventional screening and/or structure
modification rather than a mechanism-driven design.
Therefore, drug identification is usually conducted via in
vivo screening tests, on the basis of seizure type rather than
etiology.
This review presents new anticonvulsant agents
representing various structures for which the precise
mechanism of action is still not known. The newer agents
include heterocyclic compounds, sulfonamides, amino acids,
amides, enaminones and others. These new structural classes
of compounds can be useful for the design of future targets
and development of new drugs.
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THE ANTICONVULSANT SCREENING PROJECT
(ASP)
Many of the compounds presented in this review have
been tested according to the procedure established by the
Antiepileptic Drug Development (ADD) Program [25, 26].
Since 1975, the Epilepsy Branch of the National Institute of
Neurological Disorders and Stroke, National Institute of
Health, through its Antiepileptic Drug Development (ADD)
Program, has collaborated with the pharmaceutical industry
in developing new therapeutic agents for the treatment of
seizure disorders. In 1993 felbamate, the first new drug in
nearly two decades, was approved for sale in the United
States. Felbamate’s development was a collaborative effort
of both a pharmaceutical sponsor and the ADD Program.
Two other drugs, topiramate and remacemide have been
identified in the Branch’s preclinical evaluation and are now
in late clinical development. Several other drugs, losigamone,
retigabina, soretolide and rufinamide (Fig. 1) are now in
early clinical development [27-29]. The ADD Program
boasts of both preclinical and clinical trial components. The
preclinical component consists of drug discovery and
toxicology elements. The Anticonvulsant Screening Project
uses for its initial screening procedure two major convulsant
tests: maximal electroshock (MES) and subcutaneous
pentylenetetrazole (scPTZ) as well as a toxicity screen
(rotorod in mice, positional sense and gait in rats). The MES
is a model for generalized tonic-clonic seizures. The
behavioral and electrographic seizures generated in this
model are consistent with the human disorder [30]. This
model identifies those compounds which prevent the spread
of seizures. The scPTZ seizure test is a model which
primarily identifies compounds that raise seizure threshold.
The behavioral seizure produced is not typical of absence
epilepsy but clonic in nature. Like other rodent models of
absence seizures, PTZ-induced seizures are potentiated by γ-
aminobutyric acid (GABA) agonist. With some minor
exceptions, the pharmacological profile of the scPTZ seizure
model is consistent with the human condition [30, 31]. All
clinically active anticonvulsants have been found to be
protective in at least one of these two tests.
Compounds that possess significant anticonvulsant
activity in rats and in mice and do not exhibit substantial
neurotoxicity or lethality are considered for the ADD
Program’s multiphase evaluation to establish a compound’s
pharmacodynamic/pharmacokinetic profile. During the past
five years, over 4000 compounds have been evaluated by the
ADD Program. Selected results of these evaluations have
been published and are presented in this review.
NEW ANTICONVULSANT AGENTS: STRUCTURE –
ACTIVITY – RELATIONSHIPS
Heterocyclic Analogs of Carabersat
Carabersat (SB-204269) was originally designed by
modifying the structure of cromakalim (Fig. 2). This later
drug represents a class of antihypertensive agents which act
via the relaxation of vascular smooth muscle caused by the
opening of ATP-sensitive potassium channels. The
potassium channel activators which more readily penetrate
the central nervous system (CNS) may have therapeutic
potential in the treatment of epilepsy [11]. Replacement of
the 2-pyrrolidinone group of cromakalim by the fluoro-
benzoylamino group has introduced anticonvulsant activity
[32]. Carabersat, the benzopyran derivative, is a chemically
novel AED with a novel mechanism of action and a
stereospecific CNS binding site. It has potent oral
anticonvulsant properties in a range of rat seizure models,
with potency and efficacy equivalent to or better than
carbamazepine and lamotrigine. Carabersat is currently being
proposed for the treatment of epilepsy and migraine
prophylaxis [33, 34]. Subsequent exploration of structure-
activity-relationships, using high-throughput screening of the
novel SB-204269 binding site led to the identification of
anticonvulsant active series of the isomeric tetrahydro-
isoquinolinyl (THIQ) benzamides 5-, 7- and 8-substituted
[35, 36]. Compound SB-270664, the 7-substituted THIQ was
Fig. (1).  Chemical structures of new anticonvulsant drugs. Fig. (2). The structure of cromakalim and carabersat.
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reported as a promising key lead compound with high
affinity at the [3H]-SB-204269 binding site (pKi 8.9), but was
later found to have poor pharmacokinetic properties. The
major routes of metabolism of this compound were
hydroxylation of the THIQ benzo ring, N-demethylation and
aromatization to the isoquinolinium species. Starting from a
series of 7-linked THIQ derivatives, a new series of 8,8-
dimethylnaphthyridine compounds has been identified (Fig.
3). In this series a gem dimethyl group is incorporated to
prevent aromatization, and replacement of the THIQ benzo
ring with pirydyl represents an attempt to reduce
hydroxylation. In this new series, compound 1 was identified
as new potential agent displaying excellent anticonvulsant
activity and an encouraging pharmacokinetic profile in vivo .
Compound 1 has high affinity at the [3H]-SB-204269
binding site (pKi 8.7), suggesting a novel mechanism of
action, comparable with carabersat. In vivo , the rat maximal
electroshock threshold (MEST) test at 2 mg kg-1 p.o.
compound 1 showed a good level of anticonvulsant activity.
In the rat supraMES model, analysis by ‘ALLFITrd-quo
compound 1 produced an ED50 value of 3.9 mg kg
-1. This
figure is comparable with that obtained with carabersat in the
same model under identical conditions (ED50 of 6.3 mg kg
-1).
Compound 1 has excellent aqueous solubility (>1 mg mL-1)
and has been shown to have an encouraging pharmacokinetic
profile and good in vivo activity in preclinical anticonvulsant
models in rats [37].
Fig. (3). Heterocyclic analog of carabersat.
Sulfonamides
Acetazolamide {N-(5-aminosulfonyl)-1,3,4-thiadiazol-2-
yl acetamide} and methazolamide are old members of this
class, which have shown anticonvulsant activity (Fig. 4).
These drugs are bifunctional 5-membered heterocycles,
comprised of a sulfonamide and an amide as well as a 1,3,4-
thiazole nucleus, constituting potent carbonic anhydrase
(CA) inhibitors. Several new sulfonamide CA inhibitors such
as topiramate and zonisamide have been and are still used as
antiepileptic drugs (Fig. 4). The anticonvulsant effects of
these or related sulfonamides are probably due to CO2
retention secondary to the inhibition of red cell and brain
enzymes, but other mechanisms of action, such as blockade
of sodium channels and kainite/AMPA receptors, as well as
enhancement of GABA-ergic transmission, have also been
hypothesized/proven for some of these drugs. Acetazolamide
and methazolamide are still clinically used nowadays in
some forms of epilepsy, but they are considered to belong to
a minor class of antiepileptic agents. The recently developed
drug topiramate is a very effective antiepileptic, and it
also acts as a strong CA inhibitor with a potency similar to
that of acetazolamide against the physiologically important
isoenzyme CA II [38-40]. Acetazolamide, topiramate and
zonisamide possess a sulfamate moiety, which is essential
for their anhydrase inhibition. Several new carbonic
anhydrase inhibitors derivatives of sulfonamide have been
developed by Scozzafava, Supuran and coworkers [41-46]. A
series of aromatic/heteroaromatic sulfonamides incorporating
valproyl and other lipophylic moieties has been found to
possess potent CA inhibitory properties as well as
anticonvulsant in vivo effects. The hybride compound,
valproyl derivative of acetazolamide (5-valproylamido-1,3,4-
thadiazole-2-sulfonamide, 2) was one of the best hCA I and
hCA II (human cloned isoenzymes) inhibitors in the series
and it exhibited very strong anticonvulsant properties in the
MES test in mice [45]. Inhibition data of carbonic anhydrase
Ki (nM) hCA I and hCA II are as follows: for topiramate 250,
5; for compound 2 56, 6. Both drugs efficiently protected
mice against seizures induced by electroshock at a dosage of
30 mg kg-1; the protection rate was 75-100% at 0.5. h and
25-100% at 3 h after drug administration. Investigation at a
decreased dosage of 10 mg kg-1 of compound 2 showed a
rate of protection in the range of 25-44% at 0.5 h and 87-
100% at 3 h after administration. Several other 1,3,4-
thiadiazole-sulfonamide derivatives possessing potent CA
inhibitory properties and substituted with various alkyl/
arylcarboxamido/sulfonamide/ureido moieties in the 5-
position have been investigated for their anticonvulsant
effects in the same animal model. It was observed that
some lipophilic derivatives, such as 5-benzoylamido-, 5-
toluenesulfonylamido-, 5-adamantylcarboxamido-, and 5-
pivaloylamido1,3,4-thiadiazole-2-sulfonamide, show prom-
ising in vivo anticonvulsant properties and that these
compounds may be considered as interesting leads for
Fig. (4). Sulfonamide antiepileptic drugs.
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developing anticonvulsant or selective cerebrovasodilator
drugs [46]. A new series of sulfonamides incorporating
adamantyl moieties attached to the scaffolds of
aromatic/heteroaromatic sulfonamides have shown good
inhibitory potency against two human CA isozymes,
compound 3 and 4 (Fig. 5), inhibition data of carbonic
anhydrase Ki (nM) hCA I and hCA II are as follows: for
compound 3 850, 10; for compound 4 77-, 12. The
anticonvulsant activity of these two CA inhibitors against
MES tests in mice revealed that after i.p. injection (30 mg
kg-1), compounds 3 and 4 exhibit good protection against
electrically-induced convulsions (>90%). Their ED50 values
were 3.5 and 2.6 mg kg-1, respectively.
Fig. (5). Anticonvulsant sulfonamides carbonic anhydrase
inhibitors.
Derivatives of Amino Acids
Amino acids that are functionalized at both the N- and C-
terminal are proven potent anticonvulsant agents [47-72]. In
the recent years, Kohn and coworkers have reported on the
anticonvulsant activity of a series of functionalized amino
acids [47-61] (FAA) 5 (Fig. 6). A structure activity
relationships study of over 250 compounds has yielded 12
compounds with anticonvulsant activity in rodents that is
equal to or greater than phenytoin according to the MES-
seizure test. N-Benzyl-2-acetamidopropionamide 9 was the
parent compound in this series [55]. These investigations
have enabled the selection of (R)-N-benzyl-2-acetamido-3-
methoxy-propionamide 10 as the lead compound (Table 1).
Compound 10 has now entered phase II clinical trials for the
treatment of epilepsy and neuropatic pain. Extensive SAR
study of FAA 5 revealed that the N-terminus is an important
FAA structural unit. In the initial design of FAA, the N-
terminal amine was protected as an amide to provide
compounds with increased lipophilicity. Subsequent studies
demonstrated the importance of the acetamido unit (R1
=C(O)CH3) for potent anticonvulsant activity and showed
that either a decrease (i.e., R1 = C(O)H) or increases (i.e., R1
= C(O)CH2CH3, C(O)C(H)CH3)2, C(O)CCH3)3) in the size
of this moiety led to reduced activity. Furthermore, when the
acetamido (CH3C(O)NH) unit in 5 was replaced with methyl,
methoxy, hydroxyl, acetoxy, or halogen, the obtained
compounds exhibited diminished anticonvulsant activity.
Structural modifications also included replacing the C(2) unit
with the corresponding N(2) group giving the structurally-
related semicarbazide derivatives 6 [57]. Evaluation of aza
analogues 6 of functionalized amino acids in both mice (i.p.)
and rats (p.o.) showed that the compounds exhibited
significant anticonvulsant activities but in most cases at
levels lower than their amino acid counterparts. Comparison
of a selected series of semicarbazides 6 with their FAA
counterparts 5 showed that replacing the tetrahedral C(2)
carbon in 5 with a trivalent N led to a reduction in
pharmacological activity in most cases upon administration
to mice (i.p.). It was found that oral administration of the
N(2)-substituted semicarbazides to rats led to improved
anticonvulsant activities. Of the investigated compounds, 1-
acetyl-4-benzyl-2-(thiazol-2-yl)-semicarbazide 11 displayed
moderate-excellent activity in mice (MES i.p. ED50 = 22 mg
kg-1, PI = 5.4) and excellent activity in rats (MES p.o. ED50 =
6.2 mg kg-1, Tox TD50 > 250) which exceeded that of
phenytoin (Table 1).
Conformationally restricted analogues of anticonvulsant
functionalized amino acids have also been investigated [56].
Four peptidomimetic compounds of parent FAA 9 such as
1,5-disubstituted tetrazole 12, 3-substitued 1-benzyl-
pyrrolidin-2-one 13, proline 14, and (thio)hydantoins 15, 16
as well as peptidomimetic FAA derivatives have been
evaluated (Fig. 7). No improvement in pharmacological
activity was observed upon conformational constraint,
however new important information on the SAR of FAAs
was obtained. It was shown that FAAs(1)-alkylation did not
reduce anticonvulsant activity while N(3)-alkylation led to
appreciable activity loss. These studies also revealed that
derivatives of hydantoin 15 and thiohydantoin 16, upon p.o.
Fig. (6). The schematic structure of anticonvulsant derivatives of
amino acids.
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administration, respectively, displayed activity comparable
with phenytoin in the MES-seizure test in rats. The ED50
value for compound 15 in rats (p.o.) was 27 mg kg-1, while
compound 16 protected half of the rats tested at 40 mg. After
i.p. administration of compound 16 in rats, the ED50 value
was impressive, at 12 mg kg-1 in the MES-seizure test. Both
compounds possessed moderate-to-good activity in the
scPTZ-seizure test in mice. The most active compound was
16 (ED50 = 46 mg kg
-1, PI = 2.5). These findings contrasted
with the lack of scPTZ-activity exhibited by FAA analogues
9, 10 and phenytoin. It was concluded, that FAAs and their
monosubstituted hydantoin analogues exhibited different
anticonvulsant profiles. The activities of compounds 9, 10
and 15 in the volatage-sensitive Na+ channel test using
patch-clamp electrophysiology techniques were tested.
Hydantoin 15 exhibited significant voltage-dependant
blockade of Na+ channels (35% blockage at -60mV), while
the two FAAs (9 and (R)-10) had no significant effect on
peak current at 100 µM. Two prototypical antiepileptic Na+
channel blockers, phenytoin and lamotrigine, provided 48
and 53 % blockage at -60mV, respectively. These findings
indicate that 15 expresses its anticonvulsant activity in part
by acting on the Na+ channel. The divergent SAR and the
different electrophysiological findings for (thio)hydantoins
and FAAs provided evidence that these two classes of
compounds function by different mechanisms.
Replacing the N-terminal amide group in FAA with
phenylethyl, styryl, and phenylethynyl units provided a
series of functionalized amido ketones (FAK) 7 [60] (Fig. 8).
It was determined that FAK exhibit excellent anticonvulsant
activities that approach those observed for their FAA
Table 1. Selected Pharmacological Data for Amino Acids Derivatives and their Reference Compounds [56].
Mice (i.p.)a Rat (p.o.)Compound
MES, ED50 PI
c MES, ED50 PI
77 [1] 5.9 48 [1] >20
8.3 [0.5] 5.2 3.8 [2] 100
22 [0.25] 5.4 6.2 [0.5] >40
phenytoin 9.5 [2] 6.9 30 [4] >100
phenobarbital 22 [1] 3.2 9.1 [5] 6.7
aED50 and TD50 values are in mg kg 
-1. Numbers in parentheses are 95% confidence intervals. The dose effect data was obtained at the ‘time of peak effect’ (indicated in h in the
square brackets).
Fig. (7). Conformationally restricted analogs of anticonvulsant functionalized amino acids (FAAs).
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counterparts in rats. The saturated FAK 17-19 displayed a
comparable activity pattern when administered to rats (p.o.)
The ED50 values for 17, 18, and 19 were 47, 23, and 18 mg
kg-1 respectively. The ED50 values for 18 and 19 compared
favorably with phenytoin (ED50 = 30 mg kg
-1) and
phenobarbital (ED50 = 9.1 mg kg
-1), and both 18 and 19
exhibited PI values that exceeded 14. The favorable activities
for FAK have been attributed to the incorporation of key R
structural units within the FAK backbone and conformation
of the terminal ketone unit.
Conversion of the acetamido unit in 5 to an amino moiety
provided amino acid amides (AAA, 8) that are likely to have
increased water solubility compared with their FAA 5
counterparts [61]. It was demonstrated that AAA 8 are potent
anticonvulsants, and that the terminal amino group is prone
to metabolic change. Among the investigated compounds, 20
displayed in MES test (i.p. mice) a protection level of ED50 =
36 mg kg -1, PI = 2.0, (p.o. rats) ED50 = 7.1 mg kg
-1, PI = 33.
The AAA anticonvulsant activity was neither strongly
influenced by the C(2) substituent nor by the degree of
terminal amine substitution (Fig. 9). The mechanism of
action of FAA remains elusive.
Fig. (9). Structure of N-substituted amino acid N-benzylamide
(AAA).
Some amino acid derivatives have also been studied by
Paruszewski and coworkers [62-67]. Amides of N-
substituted natural and anatural amino acids containing
benzylamide, 4-fluorobenzylamide, 4-methoxybenzylamide,
2-furfurylamide, phenylethylamide, 3-pirydylmethylamide,
buthylamide, isobuthylamide, usoamylamide moiety as well
as esters have been synthesized and evaluated according to
the procedure of the ASP of NINDS. Among the tested
compounds, benzylamide derivatives of β-Ala (21, 22), Ac-
D-Pro-BZA (23) and (R,S)-Me-Tzl-BZA (24) were the most
active. They exhibited (in MES test after i.p. administration
in mice), a significant protective index (PI) of 3.2 for 21
(ED50 = 31.17 mg kg
-1) and 4.3 for 22 (ED50 = 53.47 mg kg
-
1) and, following oral administration in rats, PI>18 with ED50
= 27.33 mg kg-1 for 21 and >14 with ED50 = 34.05 mg kg
-1 for
22. Benzylamide 23 protected against MES and scPTZ
seizure in mice after i.p. administration with ED50 = 64.41
mg kg-1 (MES) and ED50 =183.78 mg kg
-1 with PI = 4.5
(scPTZ). The benzylamide of N-methyl-thiazolidine-4-
carboxylic acid 24 was active in MES seizure after i.p.
administration in mice with ED50 = 29.05 mg kg
-1 and PI =
3.77. Recent studies have demonstrated that some picoline
and nicotinic acid benzylamides substituted on the phenyl
ring also possess anticonvulsant properties [65-67]. Of these,
the most active was the picolinic acid fluorobenzylamide
(Pic-FBZA 25). ED50 of the most effective amide 25 was
14.7 mg kg-1 (MES), >50 mg kg-1 (scPTZ) and PI < 3.4
against MES (rats, i.p.) [66].
SAR studies of alanine derivatives suggested that the
structure of this amino acid, especially of fragment N-Cα-C’,
is responsible for its action [62]. It was also found that with
an α-amino acid structure, and N-acyl- or N-alkyl group, a
small substituent at C-α or an aromatic amide substituent
appear to be the most useful for anticonvulsant activity [64].
The importance of the benzylamide group of anticonvulsant
active amino acids was confirmed both by Kohn’s and
Paruszewski’s research groups.
Derivatives of arylidene imidazoline-4-one amino acids
were investigated by Kieć-Kononowicz and Karolak-
Wojciechowska [68-71]. Several series of arylidene(aryl)-
imidazolidyno-4-one derivatives incorporating glycine,
modified glycine or α-alanine and modified α-alanine were
studied as a new ligand for the glycine-NMDA binding site
(iGluRs) as well as anticonvulsant agents. Selected amino
acid derivatives (26-29) presented in Fig. 10 displayed
anticonvulsant activity in MES seizure tests at a dosage of
100 mg kg-1 or less.
Fig. (10). Arylidene-imidazoline-4-one aminoacids.
Fig. (8).  Funcionalized amido ketones (FAK).
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AMIDES
Analogs of γ-vinyl GABA
Vigabatrin (γ-vinyl GABA) is being proposed as an
anticonvulsant agent with a mechanism reportedly based on
an inhibitor of GABA aminotransferase [17]. Lee and
coworkers have developed several analogs of vigabatrin as
potential dual acting prodrugs which were covalently
coupled with an amide bond of vigabatrin and GABA
mimetic substances such as GABA, γ-vinyl GABA, valproic
acid, isonipecotic acid, nipecotic acid and 2-pyrrolidinone
[73, 74]. Most of these compounds have shown moderate
anticonvulsive activities. Among them, compounds 30 and
31 displayed the most potent anticonvulsive activity and a
broader spectrum when compared to vigabatrin (Fig. 11).
Compounds 30 and 31 were active against MES (ED50 =
0.64, 0.76), scPTZ (ED50 = 0.58, 0.40), BIC (ED50 = 0.47,
0.34) and PCR (ED50 = 0.47, 0.49 mmol kg
-1) seizure tests
respectively.
Fig. (11). Analogs of γ-vinyl GABA.
N-Benzylamides of γ-hydroxybutyric Acid
Derivatives of α-substituted γ-amino-, γ-phthalimido-, γ-
acetoxy- and γ-hydroxy butyric acid, such as acids, esters
and amides, have been investigated as new potent anticon-
vulsants [75-84]. It has been shown that α-substitutes N-
benzylamides of γ-hydroxybutyric acid (GHB) are the most
potent compounds in this group, possessing anticonvulsant
activities in MES (i.p. in mice) screens. The most potent
anticonvulsants were α-(benzylamino)-γ-hydroxybutyric
acid N-benzylamide 32 and N-(2-chlorobenzylamide) 33
(Fig. 12); their ED50 being respectively 63.0 and 54.0 mg
kg-1. In the MES screen, these compounds were less active
than the commonly used anticonvulsants carbamazepine and
phenytoin, but possessed higher activity than sodium
valproate [79]. Biochemical tests have indicated that
the active amides act as allosteric modulators of
the γ-aminobutyric acid, GABAA complex, and have an
affinity to voltage-sensitive calcium channel receptors.
N-(4-methylbenzyl)amide of α-(4-phenylpiperazin-1-yl)-γ-
hydroxybutyric acid 34 displayed the binding of [35S] TBPS
([35S] tert-buthylbicyclophosphorothionate) to the chloride
channel of the GABAA receptor complex (IC50 = 95 µM)
[80]. This may be the possible mechanism mediating the
anticonvulsant effect of these compounds. The results of
pharmacological in vivo experiments with the γ-
hydroxybutyric acid amide analogues 32 and 33 have shown
that the compounds possess variable influence on the CNS in
mice [81].
Fig. (12). α-Substituted N-benzylamides of γ-hydroxybutyric acid.
SAR studies have enabled the definition of structural
elements responsible for the anticonvulsant activity of these
several series of compounds [83, 84]. These features are as
follows: the presence of the N-benzylamide fragment, a
hydrophobic unit (aryl ring) as a distal binding site and a
group which could act as an H-bond donor. It was also
concluded that a hydroxyl group was necessary for MES
activity, and more lipophylic compounds showed better
anticonvulsant properties [82].
2,6-dimethylanilides, Carboxamides
The activity of several 2-piperidinecarboxyamides in the
MES test in mice has been reported [85, 86]. Receptor
binding studies indicate that these amides demonstrated
weak binding affinity at the phencyclidine (PCP) site on the
N-methyl-D-aspartate (NMDA) receptor complex; however,
a correlation between affinity and seizure protection in the
MES test was not observed. Using N-(2,6-dimethyl)phenyl-
2-piperidinecarboxyamide 35 and N(α-methylbenzyl)-2-
piperidinecarboxamide 36 as structural leads (Fig. 13), a
variety of analogues have been synthesized and evaluated for
anticonvulsant activity in the MES test in mice [87]. The
following modifications led to an increase in MES activity:
replacement of the piperidine ring with pyridine and
movement of the carboxamide group to the 4-position, then
opening the piperidine ring. The 2,6-dimethylanilides were
the most potent compounds in the MES test in each group of
compounds (Fig. 14). The 4-pyridinecarboxamide 37 (ED50
Fig. (13). Structures of 2-piperidinecarboxamides with activity
against MES in mice.
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Fig. (14). Structures of 2,6-dimethylanilides, derivatives of
carboxamides.
= 9.7 mg kg-1, TD50 = 53.3 mg kg
-1, PI = 5.5) was highly
active in the MES test in mice. The norleucine derivative 38,
obtained by opening the piperidine ring between the 1- and
6-positions was among the most potent compounds in the
MES test in these series of compounds (ED50 = 5.8 mg kg
-1,
TD50 = 36.4 mg kg
-1, PI = 6.3). In these derivatives, the
lipophilicity of the compound and the substitution at the α-
position of the amino acid derivative played key roles in
quantitative anticonvulsant activity. Pyridinecarboxamide 37
and norleucinecarboxamide 38 were selected as useful leads
in the development of compounds with therapeutic potential
in the treatment of tonic-clonic and partial seizures in
humans.
Hydroxyamides
Brown and coworkers have evaluated a series of novel
hydroxyamides [88, 89]. Anticonvulsant testing of these
compounds revealed the lead, 3,3,3-trifluoro-2-hydroxy-2-
phenyl-propionamide 39, to have potent anticonvulsant
activity. Anticonvulsant evaluation of compound 39
administered i.p. in mice demonstrated complete (3/3 mice)
protection at a dosage of 100 mg kg-1 up to 4 h when
challenged with MES. Compound 39 also demonstrated
effectiveness against scPTZ (5/5 mice protected) for 0.5 h at
the same dosage. In rats p.o. test compound 39 protected: the
MES ED50 value was found to be 9.9 mg kg
-1, the scPTZ
ED50 was 34 mg kg
-1 and the TD50 noted at 100 mg kg
-1,
yielding a therapeutic index of 10 for the MES model and
2.6 for the scPTZ model. In this new series of compounds,
two, 40 and 41, were the most active. Analogue 41’s MES
ED50 was also determined to be 62.4 mg kg
-1 but has notably
longer-lasting effects (up to 6 h) and a TD50 over 100 mg
kg-1. Patch clamp electrophysiology studies demonstrated
significant tonic blockade of T-type calcium current by
compounds 39-41 at 1mM. Furthermore, compounds 39 and
40 induced a significant use-dependent blockade of T-type
calcium current. These results suggest that the mechanism of
anticonvulsant activity may include blockade of T-type
calcium currents. Compounds 40 and 41 are methylated
versions of compound 39 at the amide and alcohol,
respectively (Fig. 15). Summing up, compound 39 is an
active orally available anticonvulsant with similar activity to
phenytoin, and its methylated alcohol and amide have shown
similar activity.
Fig. (15). Derivatives of hydroxyamides.
Alkanolamides
In the group of alkanolamides (42), the most interesting
results were yielded by 2-N-methylaminoethanol derivative
(compound 43), which displayed anti-MES activity (i.p. in
mice) with a PI of 2.54 (ED50 of 51.8 mg kg
-1), higher than
that for valproate (ED50 = 287, PI 1.7) in the same test (Fig.
16) [90].
Fig. (16). Derivatives of 4-(benzyloxy)benzamides.
HETEROCYCLIC AGENTS
(Arylalkyl)imidazoles
One of the structurally distinct classes of antiepileptic
drugs is the (arylalkyl)imidazoles. Denzimol (+/-)-N-
[β−[4(β-phenylethyl)phenyl]-β-hydroxyethyl]imidazole and
nafimidone (1-[2-naphthoylmethyl)imidazole are examples
of a class of anticonvulsants; the (arylalkyl)imidazoles (Fig.
17) [10]. SAR studies show that anticonvulsant properties of
this group are associated with the presence of a small oxygen
functional group (such as carbonyl, ethylene dioxy, methoxy,
acyloxy and hydroxyl substituents) in the alkylene bridge in
addition to an imidazole ring and a lipophilic aryl portion
facilitating penetration of the blood barrier. The introduction
of oxime and oxime ether groups to the alkylene bridge of
(arylalkyl)imidazole as a small oxygen functional group led
to new compounds, which displayed various levels of
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Fig. (17). Structures of (arylalkyl)imidazoles antiepileptic drugs.
activity [91]. Nafimidone oxime did not exhibit any
anticonvulsant activity. O-Alkylation of nafimidone oxime,
i.e. addition of an oxime ether functional group to the
alkylene bridge of nafimidone, resulted in new compounds
possessing anticonvulsant properties. The size of the alkyl
moiety on the oxime group appears to be important for these
properties. The O-alkyl substituted compounds (44-45) were
found to be more active than the O-arylalkyl substituted
compounds (Fig. 18). Anticonvulsant activity against MES-
induced convulsion showed that compound 44 E (trans)
isomer, was the most active with ED50 17.95 mg kg
-1 and
TD50 < 150 when the drug was administered i.p. in rats.
Compound 44 and 45 showed ED50 values of 46.77 and
36.99 mg kg-1 i.p. and PI = 1.417 and 1.411 respectively in
MES test in mice.
Fig. (18). Oxime ether derivatives 44-45 of anticonvulsant
nafimidone.
Pyrrolidin-2,5-diones
Ethosuximide, a derivative of pyrrolidin-2,5-dione,
belong to a group of old antiepileptic drugs and is still used
in the treatment of epilepsy.
A great number of 3-phenylpyrrolidine-2,5-dione
derivatives with pyridyl-, aryl- and aminophenyl-moiety at
the nitrogen atom, as well as 3-arylpyrrolidine-2,5-dione
containing a 4-arylpiperazinyl-1-yl-alkyl moiety at the
nitrogen atom and 2-aza-spiro[4.4]nonane-1,3-dione have
been investigated by Obniska, Zejc and coworkers [92-96].
Pharmacological studies have shown anticonvulsant activity
in some compounds of that group. Recently, the most potent
in the series of N-[(4-arylpiperazin-1-yl)methyl derivatives
of 3-arylpyrrolidine-2,5-dione were compounds 46 and 47
(Fig. 19). In the MES test in rats (after p.o. administration)
the best ED50 = 14.18 mg kg
-1 and PI = 8.8 were recorded for
compound 46. Compound 47 was less active, with ED50 =
133.64 mg kg-1 and PI = 2.47.
Fig. (19). Derivatives of 3-arylpyrrolidine-2,5-dione.
SAR studies in this group of pyrrolidin-2,5-dione
derivatives have led to a conclusion that the following
structural elements are required for anticonvulsant activity:
an aromatic ring at the 3-position of pyrrolidine-2,5-dione
moiety and a 4-arylpiperazine fragment with selected
substituents at the phenyl ring. The introduction of a
spirocyclopentyl ring at the 3-position of pyrrolidine-2,5-
dione did not enhance the anticonvulsant activity.
Lactams
Derivatives of cyclic lactams were synthesized and
evaluated for antiepileptic activity [97-100]. One of the
compounds, α-hydroxy-α-phenylcaprolactam (48) was
particularly interesting. I.p. administration of 48 in mice,
resulted in potent anticonvulsant protection in both
anticonvulsant models tested (MES- and scMet-induced
convulsions), exhibiting an anti-MES ED50 = 63 mg kg
-1 and
anti-scMet ED50 74 mg kg
-1. New synthesized analogues of
this compound, α-benzyl-α-hydroxycaprolactam (49), α-
ethynyl-α-hydroxycaprolactam (50) and α-hydroxy-α-
(phenylethynyl)caprolactam (51) (Fig. 20) displayed
significant anticonvulsant activity [100]. For these
compounds (i.p. in mice) anti-MES activity was seen at 100
mg kg-1 for 49, anti-scMet at 300 mg kg-1 for 50 and anti-
MES and anti-scMet at 100 mg kg-1for 51. Compound 49
exhibited (oral activity in rats) an anti-MES ED50 = 86 mg
kg-1 and anti-scMet ED50 < 83 mg kg
-1. Given that the
Rotorod TD50 was greater than 330 mg kg
-1, this particular
lactam exhibited therapeutic indices exceeding 3.9 (MES)
and 4.0 (scMet). These results showed that α-benzyl-α-
hydroxycaprolactam (49) was effective in halting seizures,
while α-ethynyl-α-hydroxycaprolactam (50) was a selective
inhibitor of petite mal seizures. Compound 51 protected rats
against MES-seizures at 30 mg kg-1; no toxicity was noted.
The difference in activity between 50 and 51 was postulated
to be a result, at least partly, of the significant change in log
P from the unsubstituted terminal alkyne (-0.27) to the
phenyl-substituted alkyne (1.52). The potent activity of 51 in
all models indicated that the substituted alkynylcaprolactams
represent a new anticonvulsant structural class.
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Fig. (20). Derivatives of α-substituted caprolactams.
Semi- and Thiosemicarbazones
Semicarbazones and related compounds have a
documented and consistent role in the design of novel
anticonvulsant agents, through the work of Dimmock’s and
Pandeya’s research group [101-112]. A number of
semicarbazones, thiosemicarbazones, bis-carbohydrazones,
aryl, arylidene, aryloxyaryl semicarbazones, acetylhydrazones
and oxamoylhydrazones have been synthesized and
evaluated for anticonvulsant activity. Extensive SAR studies
have led to postulating a specific binding site of
semicarbazones. The proposed pharmacophoric requirements
in the semicarbazone molecules are: 1) aryl binding site with
a hydrophobic group; 2) hydrogen bonding domain
exemplified by the presence of the –NHCO- grouping; 3)
two electron donor systems; 4) hydrophobic binding site
whose size determines the type of activity.
Derivatives of (aryloxy)aryl semicarbazones displayed
greater protection in the MES test than the scPTZ screen
[103]. Quantification of approximately one-third of over 100
compounds tested revealed an average protection index of
approximately 9. Following oral administration to rats, a
number of compounds displayed significant potencies in the
MES screen (ED50 value of 1-5 mg kg
-1) accompanied by a
very high protection index. Later studies enabled the
selection, in the series of aryloxyaryl semicarbazones, of a
lead molecule 52 (Fig. 21). ED50 values of compound 52 in
the MES and scPTZ screens (i.p. in mice) were 48.6 and 94.1
mg kg-1, with PI figures of 4.20 and 2.17 respectively [104].
Recently, compound 53 [4-(6-chlorobenzothiazol-2-yl)-1-(3-
isatinimino)thiosemicarbazone] has also shown strong
activity in MES seizures and scPTZ screens [111]. Knowing
that isatine derivatives possess anticonvulsant properties
[113,114], compound 53 was designed as hybrid molecule
incorporating a thiosemicarbazone fragment and an isatine
molecule. Compound 53 was more potent than valproate
against MES and scPTZ tests and was more effective than
ethosuximide against MES-induced seizures, with an ED50 of
17.86 and 6.07 mg kg -1 i.p. in mice and rat p.o., respectively.
Compound 53 exhibited a PI value of 8.77 in the rat p.o.
identification in the MES screen. In the preliminary
hippocampal-kindling screen in rats (i.p.), compound 53
showed weak ability to block the expression of fully kindled
seizures. The potency and spectrum of activity of these 6-
chlorobenzothiazolyl thiosemicarbazones were comparable
to those of standard drugs, and represent a structurally novel
class for subsequent molecular modifications.
Thiadiazoles and Quinazolin-4(3H)-ones
New thiadiazolyl and thiazolidinonyl quinazolin-4(3H)-
ones have been synthesized and screened for their
anticonvulsant activity comparing with the standard AEDs
[115]. These hybrid molecules comprise two fragments,
quinazolinone and thiazolidinone, whose derivatives have
been found to show anticonvulsant properties [116]. Out of
the 30 new hybrid compounds, the most active was 54 (Fig.
22). Compound 54 at three graded doses of 7.5, 15 and 30
mg kg -1 (i.p. in mice) in MES models was found to possess
more potency than phenytoin and to be equipotent to
lamotrigine at all the three dosage levels. In the scPTZ
model, compound 54 exhibited better anticonvulsant activity
than sodium valproate at all the three tested dosages (18.5,
37 and 74 mg kg-1). SAR studies have indicated that
compounds having a 3-amino-2-methyl-6-bromoquinazolin-
4(3H)-aryl moiety showed more protection than compounds
with a 3-amino-2-methyl-quinazolin-4(3H)-aryl moiety.
Another group of new hybrid molecules represent
derivatives of 1,3,4-thiadiazoles has been obtained by adding
two heterocyclic nuclei possessing anticonvulsant activity,
namely barbituric acid and quinazolinone (Fig. 22) [117]. Of
the compounds studied, the most active one (55) displayed
activity against MES and scPTZ seizure test in mice (i.p.)
that was more potent than the standard drug. Compound 55
at three graded dosages of 17.5, 25 and 50 mg kg-1 has been
found to incur 20, 40 and 90% protection in the MES model
and 20, 50 and 90% protection against seizure in the scPTZ
model (respectively).
In the series of 2,5-disubstituted 1,3,4-thiadiazoles, two
active anticonvulsant agents (56, 57) have been found [118].
Compounds 56 and 57 have shown maximum protection (90
and 70%, respectively) comparative to sodium valproate
(80%) in the scPTZ screen. The ED50 values of the most
effective compounds 56 and 57 were 33 and 66 mg kg-1
respectively (Fig. 23).
Fig. (21). Structures of semi- and thiosemicarbazones.
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Xanhtones
A different group of substituted derivatives of xanthone
as new anticonvulsant agents has been discovered by Marona
and coworkers [119-123]. A series of alkanolamides,
alkanoamines and aminoalkanolic derivatives of 2-, 3-, 6-, 7-
xanthone have been obtained and evaluated for
anticonvulsant activity in the MES and scPTZ assays.
Several compounds have been found to be active in both
anticonvulsant tests. In a series of aminoisopropanoloxy
derivatives of 2-, 3-, or 6-xanthone, the most promising
compounds were the 3-(tert-buthyl-amino) (58) and 3-[N-
methyl-(tert-buthyl)-amino] (59) substituted 2-hydroxy-1-(2-
xanthonoxy)-propane and compound 60 [122], of which 59
was active in both anticonvulsant tests [119] (Fig. 24).
Results of quantitative anticonvulsant activity in the MES
screen (i.p. in mice) for the tested compounds were as
follows: for 58 ED50 = 42.2 mg kg
-1 PI = 1.9, for 59 ED50 =
110.0 mg kg-1 PI > 4.5, for 60 ED50 = 173.45 mg kg
-1 PI =
0.80.
In a series of alkanolamides and alkanoamines [120, 121]
2-amino- or 2-N-methylamino-1-butanol and derivatives of
7-chloroxanthone (61, 62) have been found active in both
anticonvulsant tests, displaying anti-MES activity (i.p. in
mice) with a PI in the range of 2.84-3.64 corresponding with
that for phenytoin, carbamazepine and valproate. In the MES
test, both racemate 62 (R,S) and 62 (R) isomer displayed
activity in the similar range [ED50 = 27 mg kg
-1 PI = 3.28 for
62 (R,S) and ED50 = 33.4 mg kg
-1 PI = 2.848 for 62 (R)].
Among derivatives of 6-methoxy- or 6-chloroxanthone,
the most active were 2-amino-1-propanol-, 1-amino-2-
propanol- and 1-amino-2-butanol derivatives, which
displayed anti-MES activity with a PI in the range of 2,21-
5.88. In the MES test (i.p. in mice), ED50 values were 33.89,
37.4, 41.2 and 56.2 mg kg-1 for compounds 63 (R,S), 63 (S),
64 (R,S) and 65 (R,S) respectively [121]. Recent studies of
some central effects of chiral xanthone derivatives
demonstrated differing potencies of enantiomers and a
racemic mixture of compound 65 [123].
Derivatives of Isatin
Derivatives of 1,3-dihydro-indol-2-one (isatin) have been
reported to possess anticonvulsant activity [113, 114].
Recent studies of hydrazones, Schiff and Mannich, bases of
isatin, have led to the discovery of a new anticonvulsant
agent (66) effective in both MES and scPTZ tests [124-126]
(Fig. 25). Compound 66 [3-(4-chloro-phenylimino)-5-
methyl-1,3-dihydro-indol-2-one] yielded 87% protection at
100 mg kg-1 with an ED50 value of 53.61 mg kg
-1 in the
scPTZ screen after i.p. administration in mice. This new
agent was less neurotoxic than phenytoin, and showed
greater protection than sodium valproate [124].
MISCELLANEOUS STRUCTURES
Enaminones
Scott and coworkers have synthesized a series of
enaminones bearing the aniline, benzylamine moieties and
various aromatic heterocycles such as the pyridine,
phenothiazines, and currently the isoxazole nucleus [127-
134]. The prototype compound in the aniline series of
enaminone was methyl 4-[(4-chlorophenyl)amino]-6-methyl-
2-oxo-3-cyclohexene-1-carboxylate (67). Their ethyl
analogue (68) was found to be the most promising
enaminone in the aniline series in both rat and mouse models
during preliminary pharmacological evaluation (Fig. 26). In
MES model seizures, in mice, i.p. administration of 68
resulted in an ED50 value of 16.7 mg kg
-1 and TD50 of 110.7
mg kg-1, PI = 6.6 and an ED50 value of 3.0 mg kg
-1 and TD50
> 250 mg kg
-1, PI = 83.3 p.o. administration in rats.
Fig. (22). Derivatives of thiadiazolyl quinazolin-4(3H)-ones.
Fig. (23). 2,5-Disubstituted 1,3,4-thiadiazoles.
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Compound 68 was more potent than phenytoin, however it
was proposed that the enaminones possessed an
anticonvulsant profile similar to phenytoin. Compound 68
was then evaluated for sodium channel binding activity. It
provided a statistically significant block (P< 0.05) at -60mV,
however the blockade was not strong enough to conclude
that this was its principal mechanism of action. A
biotransformation pathway for enaminones was also
investigated [134]. The pharmacokinetic evaluation of 68
indicated that the carboalkoxy substituent converted in a two
step reaction involving deesterification and decarboxylation
to a second active enaminone metabolite 69 (Fig. 27). The 5-
methyl ketone (69) in the MES screens displayed an an ED50
value of 40.4 mg kg-1 and TD50 of 93.6 mg kg
-1, PI = 2.3,
TPE 0.25 in mice, i.p. and in rats p.o. an ED50 value of 14.7
mg kg-1 and TD50 > 186 mg
-1, PI = 12.7, TPE 1.6.
Fig. (25). Schiff base of isatin.
The anticonvulsant activity of a series of enaminone-
derived isoxazoles provided a potent, orally active class
of compounds [131]. Two series of enaminones possessing
the isomeric 5-methyl-substituted isoxazoles and 3-
methylsubstituted isoxazoles revealed both similarities and
differences with regard to anticonvulsant activity (Fig. 28).
The most potent anti-MES were three compounds in the 3-
amino series: ethyl ester 70 (ethyl 4-(5-methyl-3-isoxazolyl)
amino]-6-methyl-2-oxo-3-cyclohexene-1-carboxylate), ED50
68.9 mg kg-1, p.o. in rats TD50 > 500 mg kg
-1, PI > 49.6;
methyl ester (71), ED50 68.9 mg kg
-1 i.p. in mice, TD50 > 500
mg kg -1, PI > 7.3, and tert-buthyl ester (72), ED 50 28.1 mg
kg-1 p.o. in rats, TD50 > 500 mg kg
-1, PI > 17.8. Sodium
channel binding studies, as well as evaluations against
pentylenetetrazol, bicuculline, and picrotoxin on izoxazole
70 were all negative, leading to an unknown mechanism of
action. X-ray diffraction patterns of a representative of the 3-
amino series of isoxazoles displayed the existence of
intramolecular hydrogen bonding of nitrogen to the vinylic
proton in the cyclohexane ring, providing a pseudo-three ring
Fig. (26). Structures of anticonvulsant enaminones.
Fig. (24). Derivatives of xanthone.
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structure which was also detected previously in vinylic
benzamides. According to the authors, the activity-inactivity
of the 3-amino and 5-amino, isoxazoles may be due to the
orientation of the pseudo-three ring system.
SUMMARY
The presented review summarizes ongoing medicinal
chemistry investigations in search for new anticonvulsant
compounds. Many of the compounds presented in this
review have been evaluated by the ADD Program. Their
anticonvulsant activity has been confirmed through in vivo
screening tests, although for many compounds the precise
mechanism of action is still not known. Some of the newer
anticonvulsant agents represent structural modifications of
pre-existing compounds, while others have been developed
with the specific objective of modifying targets. These new
agents belong to several different chemical classes. Some of
them represent compounds bearing five-membered or other
heterocyclic rings in their structure; additionally, numerous
studies have demonstrated that derivatives of amino acids
can function as potential new anticonvulsant agents. The
most common structural elements of many active compounds
are an amide bond (particularly a benzylamide group) and
the presence of at least one aryl unit. New data has also
confirmed that the lipophilicity of new active molecules is an
important factor affecting their anticonvulsant potency.
These new agents can be used for the design of future targets
and development of new drugs. The discovery of a number
of active leads may also ultimately help elucidate the
mechanism of action of these new anticonvulsants.
ABBREVIATIONS
AED = Antiepileptic drug
ASP = The Anticonvulsant Screening Project
ADD
program = Antiepileptic Drug Development program
MES = Maximal electroshock
scPTZ = Subcutaneous pentylenetetrazole
scMet = Subcutaneous metrazol
GABA =  γ-aminobutyric acid
THIQ = Tetrahydroisoquinoline
MEST = Maximal electroshock threshold
ED50 = The median effective dose
TD50 = The median toxic dose
PI = Protective index
PI = TD50 / ED50
CA = Carbonic anhydrase
hCA = Human cloned isoenzymes
i.p = Intraperitoneally
p.o. = Orally
BIC = Bicuculline
PCR = Picrotoxin
SAR = Structure-activity-relationships
FAA = Functionalized amino acid
FAK = Functionalized amindo ketones
AAA = Amino acid amides:
Fig. (27). A biotransformation pathway of  enaminone 68.
Fig. (28). The isoxazolylamino enaminones.
CH3
COOC2 H5
O
HN
Cl
CH3 O
HN
COOH
Cl
CH3 O
HN
Cl
68 69
O
N
COOR
OCH3
HN
CH3
O
OCH3
HN
CH3
H
N
COOC2H5
 71 R = methyl , 72 R = tert-buthyl70
82    Current Topics in Medicinal Chemistry,  2005, Vol. 5, No. 1 Barbara Malawska
AMPA = α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid
NMDA = N-methyl-D-aspartate
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Structure and activity studies of glycine receptor ligands. Structural
remarks on arylidene-imidazoline-4-one glycinates and
glycinamides. J. Mol. Srtuct. 2001, 597, 73-81.
[71] Karolak-Wojciechowska, J.; Mrozek. A.; Kieć-Kononowicz, K.;
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